[ Main Page | Editorial Board | About | Instructions ]
[ Table of Contents | Archive | Archive Search | Online Submission | E-mail ]

Turkish Journal of Cancer
1996, Volume 26, Number 4, Page(s) 159-164
[ Summary ]
Prevention of chemotherapy-induced emesis in patients with germ cell tumors receiving multiple-day cisplatin-based chemotherapy: efficacy and tolerability of tropisetron
HALUK ONAT, SEVİL E. İNANÇ, PINAR SAİP, ERKAN TOPUZ
Division of Medical Oncology, Institute of Oncology, University of Istanbul-Turkey

Effective antiemetic therapy is a requisite for compliance to treatment in germ cell tumors, where 5-day cisplatin-based emetogenic chemotherapy is potentially curative. A phase II trial to test the efficacy of a novel 5HT3 antagonist, tropisetron, was conducted in 21 chemotherapy-naive patients with germ cell tumors destined to receive multiple-day cisplatin containing chemotherapy. Major response was defined as 0-2 episodes of vomiting, none/mild nausea, none/mild disruption of nutrition; complete responders were reported as a fraction of those with major response. Overall major and complete responses for vomiting, nausea, and nutrition were 71.4% and 33.3%; 51.7% and 28.6; and 61.6% and 38.1%, respectively. Five patients (23.8%) were unresponsive in all aspects. Two patients with initial complete protection experienced late-onset emesis leading to significant weight loss. These patients benefited from the addition of dexamethasone to tropisetron and maintenance with domperidone. Tropisetron proved to be an effective and well-tolerated antiemetic in patients receiving multiple-day cisplatin-based chemotherapy. The addition of dexamethasone to improve response rates in subsequent cycles and testing of the durability of response in multiple courses should be the goals of further studies.

[ Summary ]
[ Main Page | Editorial Board | About | Instructions ]
[ Table of Contents | Archive | Archive Search | Online Submission | E-mail ]